• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?

作者信息

Mak Joyce Wy, Sung Joseph Jy

机构信息

Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, SAR, China.

出版信息

J Gastroenterol Hepatol. 2019 Aug;34(8):1269-1270. doi: 10.1111/jgh.14817.

DOI:10.1111/jgh.14817
PMID:31456235
Abstract
摘要

相似文献

1
The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?生物制剂和生物类似药在亚洲炎症性肠病患者中的应用：我们准备好了吗？
J Gastroenterol Hepatol. 2019 Aug;34(8):1269-1270. doi: 10.1111/jgh.14817.
2
Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?炎症性肠病的生物类似药：医疗保健专业人员如何帮助解决患者的担忧？
Expert Rev Gastroenterol Hepatol. 2019 Feb;13(2):143-155. doi: 10.1080/17474124.2019.1553617. Epub 2019 Jan 17.
3
Insights on the use of biosimilars in the treatment of inflammatory bowel disease.生物类似药在炎症性肠病治疗中的应用见解。
World J Gastroenterol. 2017 Mar 21;23(11):1932-1943. doi: 10.3748/wjg.v23.i11.1932.
4
Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.加拿大强制性非医学转换生物制剂治疗风湿性疾病和炎症性肠病的潜在成本影响。
Clin Pharmacol Ther. 2021 Mar;109(3):739-745. doi: 10.1002/cpt.2042. Epub 2020 Oct 3.
5
ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).ECCO 立场声明：生物类似药在炎症性肠病（IBD）治疗中的应用。
J Crohns Colitis. 2013 Aug;7(7):586-9. doi: 10.1016/j.crohns.2013.03.011. Epub 2013 Apr 25.
6
Forum discusses biosimilars, better biologicals.论坛讨论生物类似药及更优质的生物制品。
Am J Health Syst Pharm. 2011 Dec 1;68(23):2210. doi: 10.2146/news110081.
7
Biosimilars versus biologics for inflammatory conditions.用于炎症性疾病的生物类似药与生物制品对比
Can Fam Physician. 2019 Sep;65(9):636.
8
Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.生物制剂和其他新型药物在治疗炎症性肠病中的应用进展。
Curr Opin Pharmacol. 2017 Dec;37:65-71. doi: 10.1016/j.coph.2017.09.007. Epub 2017 Oct 6.
9
Biologicals and how they revolutionized rheumatology.生物制剂及其如何彻底改变了风湿病学。
Wien Med Wochenschr. 2015 Jan;165(1-2):1-2. doi: 10.1007/s10354-015-0343-z.
10
Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.英夫利昔单抗生物类似药在炎症性肠病中的应用：一项管理性转换方案的结果。
J Crohns Colitis. 2017 Jun 1;11(6):690-696. doi: 10.1093/ecco-jcc/jjw216.

引用本文的文献

1
Comparison of 1-Year Clinical Course in Patients With Newly Diagnosed Inflammatory Bowel Disease Between Vietnam and Korea: A Multinational, Multicenter Retrospective Cohort Study.越南和韩国新诊断炎症性肠病患者1年临床病程比较：一项跨国、多中心回顾性队列研究
JGH Open. 2025 Feb 17;9(2):e70106. doi: 10.1002/jgh3.70106. eCollection 2025 Feb.
2
Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition.优化5-氨基水杨酸治疗中度溃疡性结肠炎：亚太、中东和非洲炎症性肠病联盟的专家建议
Intest Res. 2025 Jan;23(1):37-55. doi: 10.5217/ir.2024.00089. Epub 2024 Nov 4.
3
IBD barriers across the continents - East Asia.
各大洲的炎症性肠病障碍——东亚地区
Therap Adv Gastroenterol. 2023 Nov 22;16:17562848231212089. doi: 10.1177/17562848231212089. eCollection 2023.
4
Conception of National Biologics Registry for Pediatric Rheumatology: Need of the Hour and the Way Forward.国家儿童风湿病生物制剂注册中心的构想：当下的需求与前进的方向。
Indian Pediatr. 2022 Dec 15;59(12):913-915. doi: 10.1007/s13312-022-2661-8. Epub 2022 Sep 9.
5
Nomogram to predict primary non-response to infliximab in patients with Crohn's disease: a multicenter study.预测克罗恩病患者对英夫利昔单抗原发性无反应的列线图：一项多中心研究
Gastroenterol Rep (Oxf). 2020 Nov 12;9(4):329-338. doi: 10.1093/gastro/goaa069. eCollection 2021 Aug.
6
Schistosoma japonicum peptide SJMHE1 inhibits acute and chronic colitis induced by dextran sulfate sodium in mice.日本血吸虫肽 SJMHE1 抑制葡聚糖硫酸钠诱导的小鼠急性和慢性结肠炎。
Parasit Vectors. 2021 Sep 6;14(1):455. doi: 10.1186/s13071-021-04977-y.
7
Revisiting Inflammatory Bowel Disease: Pathology, Treatments, Challenges and Emerging Therapeutics Including Drug Leads from Natural Products.重新审视炎症性肠病：病理学、治疗方法、挑战及新兴疗法，包括来自天然产物的药物先导物
J Clin Med. 2020 Apr 28;9(5):1273. doi: 10.3390/jcm9051273.
8
Relapse From Deep Remission After Therapeutic De-escalation in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.缓解后治疗降级导致炎症性肠病复发：系统评价和荟萃分析。
J Crohns Colitis. 2020 Oct 5;14(10):1413-1423. doi: 10.1093/ecco-jcc/jjaa087.